First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateaui ...

RT Ivan 🧳 (@ivan_nomadz)The smartest pre-seed builders aren't chasing VCs. They're leveraging grants.Solana's ecosystem offers some of the most founder-friendly funding available - non-dilutive capital that lets you build without giving up equity or control.Here are 7 active Solana grant programs you can apply to right now:🔹 Solana Foundation@SolanaFndn is supporting ecosystem growth through strategic funding for developers, researchers, and validators building core infrastructure and public goods.🔹 Superte ...

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Today, RBC iShares expands its iShares Core exchange traded fund (ETF) lineup with the launch of the iShares Core S&P Total U.S. Stock Market Index ETF (CAD-Hedged) (the ‘iShares Fund’). The iShares Fund will provide investors with broad-based exposure to the total U.S. equity market, covering large-, mid-, small-, and micro-capitalized companies. The iShares Fund is a Canadian dollar-hedged offering and complements the iShares Core S&P Total U.S. Stock Market Inde ...

EARNINGS RELEASE & FINANCIAL SUPPLEMENT First Quarter 2022 Financial Supplement First Quarter 2022 Table of Contents | Overview | PAGE | | --- | --- | | Corporate Profile | 3 | | Earnings Release | 5 | | Selected Quarterly Financial Data | 13 | | Financial Information | | | Consolidated Balance Sheets | 15 | | Consolidated Statements of Operations | 16 | | Reconciliation of Net (Loss) Income to NAREIT FFO, Core FFO and AFFO | 17 | | Reconciliation of Net (Loss) Income to EBITDA, NAREIT EBITDAre, and Core EB ...

Financial Supplement Third Quarter 2022 Financial Supplement Third Quarter 2022 Table of Contents | Overview | PAGE | | --- | --- | | Corporate Profile | 3 | | Earnings Release | 5 | | Selected Quarterly Financial Data | 16 | | Financial Information | | | Consolidated Balance Sheets | 18 | | Consolidated Statements of Operations | 19 | | Reconciliation of Net Income (Loss) to NAREIT FFO, Core FFO and AFFO | 20 | | Reconciliation of Net Income (Loss) to EBITDA, NAREIT EBITDAre, and Core EBITDA | 22 | | Acqui ...

EARNINGS RELEASE & FINANCIAL SUPPLEMENT Third Quarter 2023 Financial Supplement Third Quarter 2023 Table of Contents | Overview | PAGE | | --- | --- | | Corporate Profile | 3 | | Earnings Release | 5 | | Selected Quarterly Financial Data | 15 | | Financial Information | | | Consolidated Balance Sheets | 17 | | Consolidated Statements of Operations | 18 | | Reconciliation of Net (Loss) Income to NAREIT FFO, Core FFO and AFFO | 19 | | Reconciliation of Net (Loss) Income to EBITDA, NAREIT EBITDAre, and Core EB ...

裁定书显示：申请人某投资基金（有限合伙）、某创业投资有限公司、某股权投资基金合伙企业（有限合伙）、某发展基金合伙企业（有限合伙）向中国国际经 济贸易仲裁委员会申请财产保全，请求查封、扣押或冻结被申请人吴某价值212618707.99元的财产。担保人阳光财产保险股份有限公司北京分公司提供保证担保。 对此，吴世春在24日通过朋友圈进行回应：这只是一个正常的诉前保全，由于基调网络在C轮融资后未能重新登陆资本市场，投资者退出受阻，可能因此触发了投 资协议中的回购条款，导致投资方发起仲裁，要求听云公司履行股权回购责任。同时，他也强调目前并未进入执行阶段，其个人财产不会受牵连，仅以其持有的 听云公司股权价值为限。 即便在创投圈身处寒冷与死寂的当下，也从不缺乏大佬的故事。最近，一份北京法院民事裁定书显示，梅花创投吴世春所掌控的超2亿元的资产遭到查封、扣押或 冻结。 最会说脱口秀的"投资界快狼" 作为梅花创投创始合伙人，吴世春的投资风格以"快，准，稳"著称，十年接触过五六万个项目。在梅花创投刚起步的时候，吴世春投的多是熟人，因此决策迅速， 最快的只要20分钟，打印协议立马签字，前后可能也就一杯咖啡的功夫。之后也开始投资陌生人 ...

Core Viewpoint - Appili Therapeutics has successfully re-launched LIKMEZ™ (ATI-1501), a metronidazole oral suspension, and is actively pursuing funding opportunities to support its development programs and enhance its market position [2][3][14]. Group 1: Product Development and Market Position - LIKMEZ™ (ATI-1501) is the first FDA-approved, ready-to-use liquid oral suspension of metronidazole, specifically designed for patients who have difficulty swallowing tablets or are sensitive to taste [3][4]. - The re-launch of LIKMEZ follows new patent coverage extending to 2039, marking a significant milestone for the company and its partner, Saptalis Pharmaceuticals [2]. - Appili is focused on driving continued sales of LIKMEZ while advancing other product candidates, including ATI-1701 and ATI-1801 [3]. Group 2: Funding and Financial Performance - The company has submitted five non-dilutive funding proposals to the U.S. government, with a total potential value of up to US$125 million, aimed at supporting the development of critical infectious disease products [3][14]. - For the fiscal year ended March 31, 2025, Appili reported a net loss of CAD 2.6 million, which is an improvement from a net loss of CAD 3.8 million in the previous year, primarily due to increased government assistance and other income [19][20]. - As of March 31, 2025, the company had cash reserves of CAD 1.2 million, a significant increase from CAD 0.1 million a year earlier, indicating improved liquidity [21]. Group 3: Research and Development Progress - ATI-1701, a biodefense vaccine candidate for tularemia, has received approximately US$11.6 million in funding from the U.S. Air Force Academy and has shown promising results in providing protection against lethal tularemia [5][6]. - The company is actively pursuing additional funding and partnership opportunities for ATI-1801, a topical antiparasitic product that has received Orphan Drug Designation from the FDA [10][13]. - Appili has successfully completed technology transfer for the ATI-1701 manufacturing process, supporting future development activities [8].

Market Overview - The current market environment is characterized by a significant amount of cash, approximately $7 trillion, held in money-market funds, which is expected to flow into dividend-paying stocks as rates decline [2][10] - Investors have shown a tendency to react to market fears, leading to fluctuations in cash holdings within money-market funds [3] Economic Concerns - The U.S. government's deficit is projected to reach $1.9 trillion for fiscal 2025, with an additional $2.8 trillion expected from the "Big Beautiful Bill" over the next decade, raising concerns about higher Treasury yields and interest rates [4] - This situation creates a potential "doom loop" where increasing debt leads to higher servicing costs, further exacerbating the deficit [4] Investment Opportunities - As interest rates fall, yields on money-market funds and Treasuries are expected to decrease, prompting investors to seek higher income from dividend stocks [10] - Three specific dividend-paying stocks are highlighted as potential beneficiaries of this cash flow: Nuveen Quality Municipal Income Fund (NAD), Dominion Energy (D), and Union Pacific (UNP) [10] Nuveen Quality Municipal Income Fund (NAD) - NAD is currently trading at a 4.9% discount to its net asset value (NAV), providing an opportunity to purchase municipal bonds at a lower price [11] - The fund offers an 8.1% dividend yield, which is tax-free for most Americans, making it an attractive investment [13] Dominion Energy (D) - Dominion Energy offers a dividend yield of 4.9% and is positioned to benefit from the growing demand for energy, particularly in data centers [14] - The stock has potential for recovery as it has resumed dividend hikes after a previous cut, and its forward price-to-earnings ratio of 16 is below its five-year average [15] Union Pacific (UNP) - Union Pacific has a lower yield of 2.4% but is considered to have upside potential due to ongoing trade discussions and tariff negotiations that could positively impact its operations [16][17] - The company has a "Dividend Magnet" effect, indicating that its dividend growth is overdue, which could attract investor interest as cash flows from money-market funds increase [18][19]

Learn about how mutual fund sales and other types of transactions are taxed within an IRA, and discover if a sale triggers an early withdrawal penalty. https://t.co/xdQMPat6Ad ...